095 | Even at the forefront of change… what’s next?

by • August 29, 2018 • Feature Slider, Feature-Home, Featured-Slides-Home, Podcast, UncategorizedComments Off on 095 | Even at the forefront of change… what’s next?177

Welcome to another episode of Biotechnology Focus radio!

There have been some interesting developments in the last couple of weeks that are changing the scope of the life sciences industry. Some of which I get the pleasure to share with you today. As a first for Canada, Concordia University now houses a facility that will change how synthetic biology research will be conducted; Bioasis Technologies’ promising drug development may have found a way to cross the blood-brain barrier; the Centre for Commercialization of Antibodies and Biologics invests in ImmunoBiochem to advance their therapeutic candidate; and the Canadian government, as well as other investors, allocate $8.8 million to three projects in Ontario.

Keep on listening to find out more details!

 

 

NEW FACILITY AT CONCORDIA IS ABOUT TO CHANGE HISTORY OF SYNTHETIC BIOLOGY RESEARCH 

(Photo Credit: Concordia)

CROSSING THE BLOOD-BRAIN BARRIER: BIOASIS TECHNOLOGIES LEAD THE WAY WITH THEIR XB3 TECHNOLOGY PLATFORM 

CCAB INVESTS IN IMMUNOBIOCHEM TO ADVANCE THEIR THERAPEUTIC CANDIDATE 

Anton Neschadim, CEO, ImmunoBiochem Corporation (left) and Robert Verhagen, CEO, CCAB (Photo Credit: CCAB)

THE CANADIAN GOVERNMENT, AMONGST OTHERS, ALLOCATE $8.8-M TO THREE PROJECTS IN ONTARIO

The Honourable Kirsty Duncan (Photo Credit: Ontario Genomics)

Comments are closed.